Literature DB >> 8131801

Cystic fibrosis: the delta F508 mutation does not lead to an exceptionally severe phenotype. A cohort study.

G Borgo1, P Gasparini, A Bonizzato, G Cabrini, G Mastella, P F Pignatti.   

Abstract

In an attempt to ascertain a relationship between genotype and phenotype, we studied the pulmonary and nutritional status of 123 cystic fibrosis patients with known genotype at an age of 8.5-10 years. Patients represent a cohort as they are almost all those born and diagnosed in a given area and period. They were followed at a single centre using uniform diagnostic and treatment protocols. Pulmonary and nutritional status of homozygous delta 508 patients did not differ from that of compound heterozygotes or of patients with other unspecified genotypes. Pulmonary manifestations varied widely in all genotype groups. With the given number of patients, a slightly higher mortality of delta F508 homozygotes could have been coincidental. We conclude that up to the age of 8.5-10 years the severity of pulmonary lesions and nutritional deficiencies is not related to the delta F508 mutation.

Entities:  

Mesh:

Year:  1993        PMID: 8131801     DOI: 10.1007/bf01957227

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  26 in total

1.  Rapid nonradioactive detection of the major cystic fibrosis mutation.

Authors:  J Rommens; B S Kerem; W Greer; P Chang; L C Tsui; P Ray
Journal:  Am J Hum Genet       Date:  1990-02       Impact factor: 11.025

2.  Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening.

Authors:  J E Dankert-Roelse; G J te Meerman; A Martijn; L P ten Kate; K Knol
Journal:  J Pediatr       Date:  1989-03       Impact factor: 4.406

3.  Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation.

Authors:  H K Johansen; M Nir; N Høiby; C Koch; M Schwartz
Journal:  Lancet       Date:  1991-03-16       Impact factor: 79.321

4.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

Review 5.  The impact of nutrition in cystic fibrosis: a review.

Authors:  K J Gaskin
Journal:  J Pediatr Gastroenterol Nutr       Date:  1988       Impact factor: 2.839

6.  Pancreatic function and gene deletion F508 in cystic fibrosis.

Authors:  G Borgo; G Mastella; P Gasparini; A Zorzanello; R Doro; P F Pignatti
Journal:  J Med Genet       Date:  1990-11       Impact factor: 6.318

7.  Genetic determination of exocrine pancreatic function in cystic fibrosis.

Authors:  P Kristidis; D Bozon; M Corey; D Markiewicz; J Rommens; L C Tsui; P Durie
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

8.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

9.  Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis.

Authors:  G Santis; L Osborne; R A Knight; M E Hodson
Journal:  Lancet       Date:  1990-11-03       Impact factor: 79.321

10.  Association of less common cystic fibrosis mutations with a mild phenotype.

Authors:  A Curtis; R Nelson; M Porteous; J Burn; S S Bhattacharya
Journal:  J Med Genet       Date:  1991-01       Impact factor: 6.318

View more
  4 in total

1.  Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.

Authors:  R B Parad; C J Gerard; D Zurakowski; D P Nichols; G B Pier
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations.

Authors:  A Bonizzato; L Bisceglia; C Marigo; E Nicolis; C Bombieri; C Castellani; G Borgo; L Zelante; G Mastella; G Cabrini
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

Review 3.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

Review 4.  Disease-modifying genes and monogenic disorders: experience in cystic fibrosis.

Authors:  Sabina Gallati
Journal:  Appl Clin Genet       Date:  2014-07-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.